English
Home > Products > CAS NO 568-73-0

China CAS NO 568-73-0 Factory

We always think and practice corresponding to the change of circumstance, and grow up. We goal at the achievement of a richer mind and body and also the living for CAS NO 568-73-0,568-73-0,Tanshinone I, Make sure you sense absolutely absolutely free to speak to us for organization. nd we believe we are going to share the ideal trading practical experience with all our merchants.
CAS NO 568-73-0, We severely promise that we give all the customers with the best quality products and solutions, the most competitive prices and the most prompt delivery. We hope to win a resplendent future for customers and ourselves.

Related Products

Hot Products

  • 4-(1-Acetylpiperazin-4-yl)phenol

    4-(1-Acetylpiperazin-4-yl)phenol

    Product Name:4-(1-Acetylpiperazin-4-yl)phenol
    Molecular Formula:C12H16N2O2
    Molecular Weight:220.27
    CAS Registry Number:67914-60-7
  • 2-Chloro-N-methylacetamide

    2-Chloro-N-methylacetamide

    Product Name:2-Chloro-N-methylacetamide
    Molecular Formula:C3H6ClNO
    Molecular Weight:107.54
    CAS Registry Number:96-30-0
  • Ceftibuten

    Ceftibuten

    Product Name:Ceftibuten
    Molecular Formula:C15H14N4O6S2
    Molecular Weight;410.42
    CAS Registry Number;97519-39-6
  • 3,3-Dimethyl-1-butyne

    3,3-Dimethyl-1-butyne

    Product Name:3,3-Dimethyl-1-butyne
    Molecular Formula:C6H10
    Molecular Weight:82.14
    CAS Registry Number:917-92-0
  • 4-tert-Butylbenzyl chloride

    4-tert-Butylbenzyl chloride

    Product Name:4-tert-Butylbenzyl chloride
    Molecular Formula:C11H15Cl
    Molecular Weight:182.69
    CAS Registry Number:19692-45-6
  • Lomefloxacin hydrochloride

    Lomefloxacin hydrochloride

    Product Name:Lomefloxacin hydrochloride
    Molecular Formula:C17H20ClF2N3O3
    Molecular Weight;387.81
    CAS Registry Number;98079-52-8
  • Related Blog
  • Reviews

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept